Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

F. Crippa, G. L. Buraggi, E. Di Re, M. Gasparini, E. Seregni, S. Canevari, M. Gadina, M. Presti, A. Marini, E. Seccamani

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.

Original languageEnglish
Pages (from-to)724-729
Number of pages6
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number6
DOIs
Publication statusPublished - 1991

Fingerprint

Radioimmunodetection
Ovarian Neoplasms
Neoplasms
Intravenous Injections
Spleen
Carcinoma
Liver
MOv18 monoclonal antibody

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. / Crippa, F.; Buraggi, G. L.; Di Re, E.; Gasparini, M.; Seregni, E.; Canevari, S.; Gadina, M.; Presti, M.; Marini, A.; Seccamani, E.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 6, 1991, p. 724-729.

Research output: Contribution to journalArticle

Crippa, F. ; Buraggi, G. L. ; Di Re, E. ; Gasparini, M. ; Seregni, E. ; Canevari, S. ; Gadina, M. ; Presti, M. ; Marini, A. ; Seccamani, E. / Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. In: European Journal of Cancer and Clinical Oncology. 1991 ; Vol. 27, No. 6. pp. 724-729.
@article{7a2bd3ac24cb4abe8bcd84a7f012df62,
title = "Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody",
abstract = "The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3{\%} vs. 0.8{\%}) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73{\%}) showed a significant difference from the sensitivities for abdominal (61{\%}) and pelvic lesions (90{\%}). No false positive results were noted.",
author = "F. Crippa and Buraggi, {G. L.} and {Di Re}, E. and M. Gasparini and E. Seregni and S. Canevari and M. Gadina and M. Presti and A. Marini and E. Seccamani",
year = "1991",
doi = "10.1016/0277-5379(91)90174-C",
language = "English",
volume = "27",
pages = "724--729",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "6",

}

TY - JOUR

T1 - Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody

AU - Crippa, F.

AU - Buraggi, G. L.

AU - Di Re, E.

AU - Gasparini, M.

AU - Seregni, E.

AU - Canevari, S.

AU - Gadina, M.

AU - Presti, M.

AU - Marini, A.

AU - Seccamani, E.

PY - 1991

Y1 - 1991

N2 - The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.

AB - The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.

UR - http://www.scopus.com/inward/record.url?scp=0025898716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025898716&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90174-C

DO - 10.1016/0277-5379(91)90174-C

M3 - Article

VL - 27

SP - 724

EP - 729

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 6

ER -